Abstract
Objective: To evaluate the optimal sequence for the receptor tyrosine kinase inhibitors (rTKIs) sorafenib and sunitinib in metastatic renal cell cancer. Methods: We performed a retrospective analysis of patients who had received sequential therapy with both rTKIs and integrated these results into a pooled analysis of available data from other publications. Differences in median progression-free survival (PFS) for first- (PFS1) and second-line treatment (PFS2), and for the combined PFS (PFS1 plus PFS2) were examined using weighted linear regression. Results: In the pooled analysis encompassing 853 patients, the median combined PFS for first-line sunitinib and 2nd-line sorafenib (SuSo) was 12.1 months compared with 15.4 months for the reverse sequence (SoSu; 95% CI for difference 1.45-5.12, p = 0.0013). Regarding first-line treatment, no significant difference in PFS1 was noted regardless of which drug was initially used (0.62 months average increase on sorafenib, 95% CI for difference -1.01 to 2.26, p = 0.43). In second-line treatment, sunitinib showed a significantly longer PFS2 than sorafenib (average increase 2.66 months, 95% CI 1.02-4.3, p = 0.003). Conclusion: The SoSu sequence translates into a longer combined PFS compared to the SuSo sequence. Predominantly the superiority of sunitinib regarding PFS2 contributed to the longer combined PFS in sequential use.
| Original language | English |
|---|---|
| Pages (from-to) | 333-340 |
| Number of pages | 8 |
| Journal | Oncology |
| Volume | 82 |
| Issue number | 6 |
| DOIs | |
| Publication status | Published - Jul 2012 |
Fingerprint
Keywords
- Renal cell carcinoma
- Sorafenib
- Sunitinib
- Treatment regimens
- Tyrosine kinase inhibitors
ASJC Scopus subject areas
- Cancer Research
- Oncology
Cite this
A pooled analysis of sequential therapies with sorafenib and sunitinib in metastatic renal cell carcinoma. / Stenner, Frank; Chastonay, Rahel; Liewen, Heike; Haile, Sarah R.; Cathomas, Richard; Rothermundt, Christian; Siciliano, Raffaele D.; Stoll, Susanna; Knuth, Alexander; Buchler, Tomas; Porta, Camillo; Renner, Christoph; Samaras, Panagiotis.
In: Oncology, Vol. 82, No. 6, 07.2012, p. 333-340.Research output: Contribution to journal › Article
}
TY - JOUR
T1 - A pooled analysis of sequential therapies with sorafenib and sunitinib in metastatic renal cell carcinoma
AU - Stenner, Frank
AU - Chastonay, Rahel
AU - Liewen, Heike
AU - Haile, Sarah R.
AU - Cathomas, Richard
AU - Rothermundt, Christian
AU - Siciliano, Raffaele D.
AU - Stoll, Susanna
AU - Knuth, Alexander
AU - Buchler, Tomas
AU - Porta, Camillo
AU - Renner, Christoph
AU - Samaras, Panagiotis
PY - 2012/7
Y1 - 2012/7
N2 - Objective: To evaluate the optimal sequence for the receptor tyrosine kinase inhibitors (rTKIs) sorafenib and sunitinib in metastatic renal cell cancer. Methods: We performed a retrospective analysis of patients who had received sequential therapy with both rTKIs and integrated these results into a pooled analysis of available data from other publications. Differences in median progression-free survival (PFS) for first- (PFS1) and second-line treatment (PFS2), and for the combined PFS (PFS1 plus PFS2) were examined using weighted linear regression. Results: In the pooled analysis encompassing 853 patients, the median combined PFS for first-line sunitinib and 2nd-line sorafenib (SuSo) was 12.1 months compared with 15.4 months for the reverse sequence (SoSu; 95% CI for difference 1.45-5.12, p = 0.0013). Regarding first-line treatment, no significant difference in PFS1 was noted regardless of which drug was initially used (0.62 months average increase on sorafenib, 95% CI for difference -1.01 to 2.26, p = 0.43). In second-line treatment, sunitinib showed a significantly longer PFS2 than sorafenib (average increase 2.66 months, 95% CI 1.02-4.3, p = 0.003). Conclusion: The SoSu sequence translates into a longer combined PFS compared to the SuSo sequence. Predominantly the superiority of sunitinib regarding PFS2 contributed to the longer combined PFS in sequential use.
AB - Objective: To evaluate the optimal sequence for the receptor tyrosine kinase inhibitors (rTKIs) sorafenib and sunitinib in metastatic renal cell cancer. Methods: We performed a retrospective analysis of patients who had received sequential therapy with both rTKIs and integrated these results into a pooled analysis of available data from other publications. Differences in median progression-free survival (PFS) for first- (PFS1) and second-line treatment (PFS2), and for the combined PFS (PFS1 plus PFS2) were examined using weighted linear regression. Results: In the pooled analysis encompassing 853 patients, the median combined PFS for first-line sunitinib and 2nd-line sorafenib (SuSo) was 12.1 months compared with 15.4 months for the reverse sequence (SoSu; 95% CI for difference 1.45-5.12, p = 0.0013). Regarding first-line treatment, no significant difference in PFS1 was noted regardless of which drug was initially used (0.62 months average increase on sorafenib, 95% CI for difference -1.01 to 2.26, p = 0.43). In second-line treatment, sunitinib showed a significantly longer PFS2 than sorafenib (average increase 2.66 months, 95% CI 1.02-4.3, p = 0.003). Conclusion: The SoSu sequence translates into a longer combined PFS compared to the SuSo sequence. Predominantly the superiority of sunitinib regarding PFS2 contributed to the longer combined PFS in sequential use.
KW - Renal cell carcinoma
KW - Sorafenib
KW - Sunitinib
KW - Treatment regimens
KW - Tyrosine kinase inhibitors
UR - http://www.scopus.com/inward/record.url?scp=84861880926&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=84861880926&partnerID=8YFLogxK
U2 - 10.1159/000338001
DO - 10.1159/000338001
M3 - Article
C2 - 22677881
AN - SCOPUS:84861880926
VL - 82
SP - 333
EP - 340
JO - Oncology
JF - Oncology
SN - 0030-2414
IS - 6
ER -